Search Results | Clinical | Eurofins-Viracor

Viracor-IBT Laboratories to Present at the American College of Allergy, Asthma and Immunology’s Annual Meeting

Location: /news-and-events/posts/2009/november/viracor-ibt-laboratories-to-present-at-the-american-college-of-allergy-asthma-and-immunology-s-annual-meeting/

Diagnostics to Differentiate Peanut Allergic from Peanut Sensitize

Location: /resource-center/posts/2023/september/molecular-peanut-component-diagnostics-differentiate-peanut-allergic-from-peanut-sensitized-patients/

Third Circuit Court of Appeals Affirms Judgment in Favor of Eurofins Viracor in Patent Infringement Case

Location: /news-and-events/posts/2022/july/third-circuit-court-of-appeals-affirms-judgment-in-favor-of-eurofins-viracor-in-patent-infringement-case/

Eurofins Viracor and Cornell University Sign Exclusive Licensing Agreement to Expand Access to Ground-Breaking Technologies for Assessing Organ and Tissue Damage in Transplant and COVID-19 Patients

Location: /news-and-events/posts/2022/march/eurofins-viracor-and-cornell-university-sign-exclusive-licensing-agreement-to-expand-access-to-ground-breaking-technologies-for-assessing-organ-and-tissue-damage-in-transplant-and-covid-19-patients/

Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients

Eurofins Viracor ExPeCT™ CAR-T multiplexed quantitative real-time PCR (qPCR) assay provides a powerful diagnostic tool to monitor and optimize CAR-T therapy.

Location: /news-and-events/posts/2023/february/eurofins-viracor-launches-ground-breaking-test-for-assessing-expansion-and-persistence-of-car-t-therapy-in-cancer-patients/

Eurofins Viracor launches Epstein-Barr Virus (EBV) inSIGHT™ to Evaluate T Cell Mediated Immunity to Epstein-Barr Virus

Location: /news-and-events/posts/2022/october/eurofins-viracor-launches-epstein-barr-virus-ebv-insight-to-evaluate-t-cell-mediated-immunity-to-epstein-barr-virus/

Eurofins Viracor Opens Expansive Laboratory in Lenexa, KS

Eurofins Viracor, a leader in infectious disease and immunology testing, today celebrated the opening of its expansive new laboratory in Lenexa, KS. The 110,000 square foot, state-of-the-art facility will be home to 450 employees, comprised of 215 current employees and 235 newly created roles and creates additional capacity to support growth in biopharma and transplant diagnostic testing services.

Location: /news-and-events/posts/2022/october/eurofins-viracor-opens-expansive-laboratory-in-lenexa-ks/

New PCR Assay for Chagas Disease Diagnosis

Eurofins Viracor launches a rapid, quantitative PCR test for accurate Chagas disease diagnosis, improving accuracy for at-risk patients.

Location: /news-and-events/posts/2025/january/eurofins-viracor-launches-new-quantitative-pcr-assay-for-chagas-disease-t-cruzi-diagnosis/

Streamline with LabAlert | Lab Access

Streamline your practice with Eurofins Viracor's LabAlert: Fast, convenient, and secure access to test results. Explore Eurofins Viracor's LabAlert app.

Location: /news-and-events/posts/2024/november/streamline-with-labalert/

Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing

Location: /news-and-events/posts/2021/july/eurofins-viracor-invests-in-innovation-with-the-launch-of-coronavirus-covid-19-sars-cov-2-insight-t-cell-immunity-testing/